Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SFCE-Metro 01 phase II metronomic chemotherapy combination in pediatric relapsed/progressing solid tumors
2010-021792-81Phase 2
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Jul 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinblastine, cyclophosphamide, methotrexate and celecoxib in Non-hematologic malignancy, sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoints: Progression-free survival at 4 months, Progression-free survival at 12 months and 2 more.
02
Drugs
vinblastinecyclophosphamidemethotrexatecelecoxib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2010-021792-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021792-81.